市场调查报告书
商品编码
1403457
到 2030 年西方印渍术市场预测:按产品、应用、最终用户和地区进行的全球分析Western Blotting Market Forecasts to 2030 - Global Analysis By Product (Consumables, Instruments and Other Products), Application (Clinical Diagnostics, Food & Beverages and Other Applications), End User and By Geography |
根据 Stratistics MRC 的数据,2023 年全球西方印渍术市场规模将达到 11.8 亿美元,预计到 2030 年将达到 21.1 亿美元,预测期内复合年增长率为 8.7%。
蛋白质分析和检测是称为西方印渍术的分子生物学技术的常见应用。西方印渍术涉及使用凝胶电泳按大小分离蛋白质,然后将分离的蛋白质转移到膜上。西方印渍术在许多科学领域中用于研究蛋白质表现、转译后修饰和相互作用。
根据美国疾病管制与预防美国(CDC)公布的资料,2020年美国将有30,635人被诊断出感染爱滋病毒。
蛋白质西方印渍术生物学和癌症等领域产生了重要的新认识。随着生物医学研究领域的发展和对精确蛋白质分析的需求的增加,西方印渍术变得至关重要。此外,西方印渍术在探索疾病、了解分子机制和检验研究结果方面的多功能性使其成为满足生物医学研究界不断变化的需求的基本工具。
西方印渍术的成本有多种原因,包括需要使用昂贵的试剂和消耗品,包括封闭剂、检测基材和抗体。成像设备和凝胶电泳系统等专用工具也会增加整体成本。此外,该技术需要熟练的人员,进一步增加了成本。执行此类测试的高成本是该市场的主要障碍。
美国卫生研究院 (NIH) 等政府机构的倡议为涉及西方印渍术技术的计划分配资金。这种支持鼓励了生物医学、药物开发和诊断领域的创新、技术进步和新应用的探索。此外,财政支持还透过为蛋白质分析及相关研究的发展创造有利的环境、加速科学发现和提高可及性来提供支持,这是市场扩张的驱动力。
实验室之间在程序、试剂和设备方面的不相容性阻碍了结果的再现性。调查方法的差异会影响资料的可靠性,并使调查结果难以比较和检验。标准化不良会损害西方印渍术的形象,引发资料准确性问题,并使研究团队难以合作。
供应链中断、物流挑战以及实验室活动的限制阻碍了西方印渍术试剂和设备的生产和分销。由于封锁,许多研究计划被推迟或停止,影响了对这些产品的需求。此外,与 COVID-19 无关的研究经费减少也限制了可用于西方印渍术研究的资源。最终,随着研究重点转向 COVID-19,注意力和资源从其他领域转移。经济不确定性正在推动科学界的成本意识并影响购买决策。
由于其在分子生物学和蛋白质研究中的重要作用,设备部分预计将占据最大份额。它在准确分离、运输和检测复杂生物样品中的蛋白质方面发挥着至关重要的作用。製造商不断创新,为研究人员提供尖端系统,这些系统融合了快速电泳、半干式或湿式转印功能以及先进的成像技术等功能。此外,这些仪器包括根据大小分离蛋白质的电泳系统、运输蛋白质的转移系统以及可视化和量化蛋白质条带的成像系统。我们正在推动这一领域的扩展。
生物製药和生物技术公司领域预计在预测期内复合年增长率最高,因为它用于药物开发、品管和研究方法中的蛋白质分析。此技术有助于评估蛋白质表现、检验治疗标靶并确保产品一致性。此外,它还透过提供对蛋白质特性的精确见解来支持生物製药开发和生物技术研究的进步。它是生物製药开发和生产的主要相关人员,并正在推动该领域的成长。
由于政府支持科学研究和开发的计划,特别是在生物技术和医疗保健领域,北美在预测期内获得了最大的市场占有率。学术机构、研究机构和产业相关人员之间的合作促进创新和应用。此外,这些产品目前符合食品药物管理局(FDA)等机构制定的法规结构规定的品质标准,确保了它们在研究和诊断方面的可靠性,从而扩大了该地区的市场。我们正在扩大规模。
由于生命科学研究中检测技术、转移策略和凝胶电泳系统的进步,预计欧洲在预测期内将呈现最高的复合年增长率。欧洲促进研究和开发的政策,加上支持生物技术和医疗保健创新的倡议,现在正在使这些程序更加准确和高效。 Boster Biological Technology、GE Healthcare、PerkinElmer Inc. 和 Danaher Corporation 等主要企业製定了严格的监管政策和品质标准,推动了该地区的成长。
According to Stratistics MRC, the Global Western Blotting Market is accounted for $1.18 billion in 2023 and is expected to reach $2.11 billion by 2030 growing at a CAGR of 8.7% during the forecast period. Protein analysis and detection are common applications of the molecular biology technique known as western blotting. It involves transferring the separated proteins onto a membrane after they have been separated by size using gel electrophoresis. Numerous scientific domains utilize western blotting to aid in the investigation of protein expression, post-translational modifications, and interactions.
According to data published by the Centers for Disease Control and Prevention (CDC), stated that in 2020, 30,635 people received an HIV diagnosis in the U.S.
The study of cellular processes, protein expression, and interactions is greatly aided by western blotting, which provides important new understandings in fields like neurobiology and cancer. It is essential as the field of biomedical research grows and the need for precise protein analysis increases. Furthermore, its versatility in exploring diseases, understanding molecular mechanisms, and validating research findings positions it as a fundamental tool, to meet the evolving demands of the biomedical research community which is driving adoption and innovation of this market's growth.
The cost of Western blotting can be attributed to several reasons, such as the fact that the procedure necessitates the use of costly reagents and consumables, including blocking agents, detection substrates, and antibodies. Specialized tools like imaging equipment and gel electrophoresis systems also raise the overall cost. Furthermore, the cost of using the technique is further increased by the requirement for skilled personnel. The high expense of carrying out these tests is one significant obstacle to the market.
Initiatives from government bodies, such as the National Institutes of Health (NIH), allocate funds to projects involving Western blotting techniques. Innovation, technical progress, and the investigation of novel uses in biomedicine, medication development, and diagnostics are all encouraged by this support. Furthermore, the financial support creates a favorable environment for developments in protein analysis and related research, speeds up scientific discoveries, and supports by improving accessibility which is driving this market expansion.
Incompatibilities across laboratories in procedures, reagents, and equipment hinder result reproducibility. Variability in methodologies impacts data reliability, making it challenging for researchers to compare and validate findings. Problems with standardization can damage Western blotting's image, raising doubts regarding the accuracy of the data and making it more difficult for research groups to collaborate.
Disruptions in supply chains, logistical challenges, and restrictions on laboratory activities have hindered the production and distribution of Western blotting reagents and instruments. Many research projects were delayed or halted due to lockdowns, impacting the demand for these products. Furthermore, the resources available for Western blotting studies have been restricted due to decreased funding for research irrelevant to COVID-19. Eventually, attention and resources have been diverted from other areas due to the shift in research priorities towards COVID-19. Economic uncertainties have prompted cost-consciousness, affecting purchasing decisions in the scientific community.
The instrument segment is estimated to hold the largest share due to its crucial role in molecular biology and protein research. They play a pivotal role in the precise separation, transfer, and detection of proteins from complex biological samples. Manufacturers continually innovate to provide researchers with state-of-the-art systems, incorporating features like rapid electrophoresis, semi-dry or wet transfer capabilities, and advanced imaging technologies. Furthermore, these instruments include electrophoresis systems for separating proteins based on size, transfer systems for transferring proteins, and imaging systems for visualizing and quantifying protein bands, which is driving this segment expansion.
The biopharmaceutical & biotechnology companies segment is anticipated to have highest CAGR during the forecast period due to the use of these companies for protein analysis in drug development, quality control, and research processes. The technique aids in assessing protein expression, validating therapeutic targets, and ensuring product consistency. Additionally, by providing precise insights into protein characteristics, it supports the development of biopharmaceuticals and the advancement of biotechnological research. It represents a key stakeholder group in the development and production of biotherapeutics, thereby boosting this segment's growth.
North America commanded the largest market share during the extrapolated period owing to government programs that support scientific research and development, especially in the biotechnology and healthcare sectors. Collaborations between academic institutions, research organizations, and industry players foster innovation and applications. Furthermore, these now meet quality standards set by regulatory frameworks established by organizations such as the Food and Drug Administration (FDA), guaranteeing dependability in research and diagnostics, thereby propelling this region's size.
Europe is expected to witness highest CAGR over the projection period due to advancements in detection technologies, transfer strategies, and gel electrophoresis systems in life sciences research. These procedures are now more accurate and efficient European policies promoting research and development, coupled with initiatives supporting biotechnology and healthcare innovation. Some of the key players including Boster Biological Technology, GE Healthcare, PerkinElmer Inc. and Danaher Corporation contribute to strict regulatory policies and quality standards which are driving this region's growth.
Some of the key players in the Western Blotting Market include Abcam Plc, Advansta, Inc., Azure biosystems, inc., Bio-Techne Corporation, Boster Biological Technology, Cell signaling technology, inc., Danaher Corporation, EMD Millipore Corporation, GE Healthcare, Hofmann-La Roche Ltd., LI-COR, Inc., Merck Kgaa, PerkinElmer Inc., Stressmarq biosciences inc. and Thermo Fisher Scientific, Inc.
In November 2023, GE HealthCare and Masimo announced a joint agreement to integrate Masimo Signal Extraction Technology (SET) pulse oximetry into GE HealthCare's Portrait Mobile wireless and wearable patient monitoring solution.
In October 2023, Thermo Fisher Scientific and Olink announced that their respective boards of directors have approved Thermo Fisher's proposal to acquire Olink for $26.00 per common share in cash, representing $26.00 per American Depositary Share (ADS) in cash.
In October 2023, GE HealthCare Announces New Innovations and Collaborations in Image Guided Therapy as part of TCT2023 Cardiology Care Pathway Showcase. As clinicians work to treat CVD, cardiology procedures continue to evolve as demand for minimally invasive surgery grows.